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The Design and Sample Size Requirement for
a Cluster Randomized Non-Inferiority Trial
with Two Binary Co-Primary Outcomes.
William F. McCarthy
Abstract
This paper will discuss the design and sample size requirement for a cluster ran-
domized non-inferiority trial with two binary co-primary outcomes. A hypotheti-
cal study (the EXAMPLE Trial) will be considered.
Lets assume the EXAMPLE Trial will consist of two separate binomial non-
inferiority two-sample trials. Trial 1: the Coronary Artery Disease known pop-
ulation (co-primary 1) and Trial 2: the Coronary Artery Disease unknown popu-
lation (co-primary 2). A physician-month cluster randomization scheme will be
used. That is, for each trial (trial 1 and trial 2) every month for a 12-month period,
each physician participating in the EXAMPLE Trial will be allocated a random-
ized cluster of size 10. The physician will need to consent and enroll 10 patients
each month for the 12-month period for each trial (trial 1 and trial 2). Each clus-
ter will be specific to a treatment group (either EXPERIMENTAL or CONTROL).
The design and sample size method discussed by Bland (2003) and Donner and
Klar (2000) will be used.
The EXAMPLE Trial will be declared a success if statistical significance is demon-
strated at the pre-specified nominal alpha-level for both co-primary outcomes.
Lets assume the EXAMPLE Trial will consist of two separate binomial non-inferiority two-sample trials. 
Trial 1: the CAD known population (co-primary 1) and Trial 2: the CAD unknown population (co-primary 
2).  A physician-month cluster randomization scheme will be used. That is, for each trial (trial 1 and trial 2) 
every month for a 12-month period, each physician participating in the EXAMPLE Trial will be allocated a 
randomized cluster of size 10. The physician will need to consent and enroll 10 patients each month for the 
12-month period for each trial (trial 1 and trial 2). Each cluster will be specific to a treatment group (either 
EXPERIMENTAL or CONTROL).  
 
The design and sample size method discussed by Bland (2003) and Donner and Klar (2000) will be used. 
 
The EXAMPLE Trial will be declared a success if statistical significance is demonstrated at the pre-specified 
nominal α -level for all co-primary outcomes.  
 
Therefore, non-inferiority must be demonstrated with respect to both co-primary 1 and co-primary 2 in 
order for the EXAMPLE Trial to be considered a success. Since both co-primary outcomes are required to be 
met, no adjustment to the significance level (α  = 0.025; 1-sided) is required (EMEA: CPMP/EWP/908/99; 
2002; section 2.1.1 and Sankoh AJ et al.; 2003; section 3.1.1). The EMEA document states: “ In this situation, 
there is no intention or opportunity to select the most favourable result and, consequently, the individual type 
I error levels are set equal to the overall type I error level α , i.e., no reduction is necessary”. 
 
However, the EMEA document notes: “This procedure inflates the relevant type II error (here: falsely 
accepting that at least one null hypothesis is true), which in the worst case scenario is the sum of the type II 
errors connected with the individual hypotheses. This inflation must be taken into account for a proper 
estimation of the sample size for the trial”.  
 
Therefore, we will need to set the type II error rate for each co-primary outcome at a value which, in the 
worst case scenario, will sum to a value no greater than 0.20 (since, for this trial, we want an overall type II 
error rate = 0.20; that is power = 80%). Thus, we will use β =0.10 for each co-primary outcome. 
 
EAST 5.2.0 will be used to determine the sample size (East, 2008).  
 
 
Trial 1: Sample Size Calculation for Co-Primary 1: 
 
 
Lets assume the study design consists of two treatment groups. CONTROL is the active control group and 
EXPERIMENTAL is the experimental treatment group. 
 
Co-primary 1 will be treated as a binomial non-inferiority two-sample trial. The goal is to establish that the 
death rate of the experimental treatment group is no worse than that of the active control group. A difference 
in proportions is considered. 
 
 
 
Co-Primary 1: Coronary Artery Disease (CAD) known: Death rate at 12 months. 
 
Denote cπ as the death rate for the active control group and tπ as the death rate for the experimental 
treatment group. 
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Let c tδ π π= − . 
 
Let the non-inferiority margin be denoted as 0δ . 
 
The null hypothesis is 0 :H 0δ δ=  and is tested against a one-sided alternative hypothesis. 
 
Since the occurrence of a response denotes patient harm rather than benefit, then 0 0δ < and the alternative 
hypothesis is 1 :H 0δ δ>  or equivalently as 1 0: t cH π π δ< − . 
 
For any given cπ , the sample size is determined by the desired power at a specified value of 1δ δ= . A 
common choice is 1 0δ =  or (equivalently t cπ π= ). For co-primary 1, 1 0δ = . 
 
The active control group death rate is assumed to be cπ = 0.042. 
The non-inferiority margin is assumed to be 0δ = - 0.011, i.e., tπ =0.053. 
 
 
 
Information Used by EAST to Calculate the Sample Size (assuming no clustering): 
  
A non-inferiority trial is considered 
Difference of proportions 
Binomially distributed data is considered  
The active control group event rate is assumed to be 0.042. 
The non-inferiority margin is assumed to be - 0.011.   
The fraction of patients assigned to each study arm is 1:1 (exp. treatment : active control) 
The "-level is 0.025 
The $-level is 0.10 (90% power) 
One-sided hypothesis testing is used 
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Results from EAST. 
 
 
 
 
A total sample size of 13, 976 is required. 
 
In order to account for the physician-month cluster design to be used in the EXAMPLE Trial, this total 
sample size of 13, 976 needs to be inflated to account for the effect of clustering. 
 
The ICC method is used to inflate the sample size to account for the effect of clustering. We will use an 
ICC=0.01. 
 
In a talk presented by J M Bland to the RSS Medical Section and the RSS Liverpool Local Group, 12 NOV 
2003, Bland stated “the magnitude of the effect of clustering is measured by the design effect, Deff, given by 
the following: Deff = 1 + (n - 1)(ICC) where n is the number of observations in a cluster and ICC is the intra-
cluster correlation coefficient. The ICC is the correlation between pairs of subjects chosen at random from 
the same cluster. It is usually quite small, 0.04 is a typical figure. This was the median ICC reported in the 
review by Eldridge et al. (2004). If n=1, cluster size one, in other words, no clustering, then Deff=1, otherwise 
Deff will exceed 1 (this assumes a positive correlation between pairs of subjects).   
 
  Page 3 
Hosted by The Berkeley Electronic Press
We can use this in two ways. In design, if we estimate the required sample size ignoring clustering, we must 
multiply it by the design effect to get the sample size required for the clustered sample. Alternatively, we can 
say that if the sample size is estimated ignoring the clustering, the clustered sample has the same power as for 
a simple sample of size equal to what we get if we divide our sample size by the design effect. In analysis, if we 
analyse the data as if there were no clusters, the variances of the estimates must be multiplied by Deff, hence 
the standard error must be multiplied by the square root of Deff. From this formula, we can see that 
clustering may have a large effect if the ICC is large or if the cluster size is large. Only one of these conditions 
need be met. For example, if the ICC is 0.001, a very small correlation, and the cluster size is 500, the design 
effect will be 1 + (500-1)x0.001 = 1.5 and we would need to increase the sample size by 50% to achieve the 
same power as an unclustered trial.  
In addition, we need to estimate variances both within and between clusters. If the number of clusters is 
small, the between clusters variance will have few degrees of freedom and we will be using the t distribution 
in inference rather than the Normal. This too will cost in terms of power.” ICC ( ρ ) is the correlation 
between pairs of patients chosen at random from the same cluster. 
2
2 2
B
B W
σρ σ σ= +  
where 2Bσ  is the between cluster variability 
where 2Wσ is the within cluster variability 
 
the size of the ICC is generally larger for smaller clusters 
 
small cluster ∼ 0 to 0.3  (large ICC) 
medium cluster ∼ 0 to 0.05 (medium ICC) 
large cluster ∼ 0 to 0.001 (small ICC) 
 
Eldridge et al. (2006) also discuss the impact of the design effect on sample size determination for cluster 
randomized trials. 
 
The EXAMPLE Trial assumes a cluster size of 10 patients (cluster = physician-month). Using Deff = 1 + (n - 
1)(ICC), we have 1 + (10-1)(0.01) = 1.09. Therefore, we need to inflate the sample size 13, 976 by 1.09 to get 
the total sample size required for co-primary outcome 1 when clustering is considered. 
 
13, 976 x 1.09 = 15, 234 patients. This would result in approximately 1, 524 clusters. 
 
 
Trial 2: Sample Size Calculation for Co-Primary 2: 
 
 
Lets assume the study design consists of two treatment groups. CONTROL is the active control group and 
EXPERIMENTAL is the experimental treatment group. 
 
Co-primary 2 will be treated as a binomial non-inferiority two-sample trial. The goal is to establish that the 
death rate of the experimental treatment group is no worse than that of the active control group. A difference 
in proportions is considered. 
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Co-Primary 2: Coronary Artery Disease (CAD) unknown: Death rate at 12 months. 
 
Denote cπ as the death rate for the active control group and tπ as the death rate for the experimental 
treatment group. 
 
Let c tδ π π= − . 
 
Let the non-inferiority margin be denoted as 0δ . 
The null hypothesis is 0 :H 0δ δ=  and is tested against a one-sided alternative hypothesis. 
 
Since the occurrence of a response denotes patient harm rather than benefit, then 0 0δ < and the alternative 
hypothesis is 1 :H 0δ δ>  or equivalently as 1 0: t cH π π δ< − . 
 
For any given cπ , the sample size is determined by the desired power at a specified value of 1δ δ= . A 
common choice is 1 0δ =  or (equivalently t cπ π= ). For co-primary 2, 1 0δ = . 
 
The active control group death rate is assumed to be cπ = 0.065. 
The non-inferiority margin is assumed to be 0δ = - 0.016, i.e., tπ =0.081. 
 
 
Information Used by EAST to Calculate the Sample Size (assuming no clustering) 
  
 
A non-inferiority trial is considered 
Difference of proportions 
Binomially distributed data is considered  
The active control group event rate is assumed to be 0.065. 
The non-inferiority margin is assumed to be - 0.016.   
The fraction of patients assigned to each study arm is 1:1 (exp. treatment : active control) 
The "-level is 0.025 
The $-level is 0.10 (90% power) 
One-sided hypothesis testing is used 
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Results from EAST. 
 
 
 
 
A total sample size of 9, 978 is required. 
 
In order to account for the physician-month cluster design to be used in the EXAMPLE Trial, this total 
sample size of 9, 978 needs to be inflated to account for the effect of clustering. 
 
The ICC method is used to inflate the sample size to account for the effect of clustering. We will use an 
ICC=0.01. 
 
 
The EXAMPLE Trial assumes a cluster size of 10 patients (cluster = physician-month). Using Deff = 1 + (n - 
1)(ICC), we have 1 + (10-1)(0.01) = 1.09. Therefore, we need to inflate the sample size 9, 978 by 1.09 to get the 
total sample size required for co-primary outcome 2 when clustering is considered. 
 
9, 978 x 1.09 = 10, 876 patients. This would result in approximately 1, 088 clusters. 
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Sample Size Requirement for the EXAMPLE Trial – One-look approach 
 
Trial 1: Sample Size Calculation for Co-Primary Outcome 1: 15, 234 --> 1, 524 clusters 
Trial 2: Sample Size Calculation for Co-Primary Outcome 2: 10, 876 --> 1, 088 clusters 
 
 
Interim Monitoring of the Co-Primary Outcomes using Lan DeMets 
 
 
The above sample sizes would have to be increased if one wanted to perform formal interim analyses using 
the Lan DeMets method. For a 3-look approach, we have the following: 
 
 
Sample Size Requirement for the EXAMPLE Trial – Three-look approach 
 
Trial 1: Sample Size Calculation for Co-Primary Outcome 1: 15, 416 --> 1, 542 clusters 
Trial 2: Sample Size Calculation for Co-Primary Outcome 2: 11, 006 --> 1, 102 clusters 
 
The Lan-DeMets (1983) procedure will be used for assessing each co-primary study outcome when the 
interim “looks” of the data are taken. This procedure allows for flexible interim monitoring while 
simultaneously preserving the type-I error of the study. An alpha spending function will be used. The rate at 
which the alpha is spent is a function of the total information available at the time of the interim analysis (i.e., 
cumulative patient accrual). A stopping boundary that preserves the spirit of the O’Brien-Fleming stopping 
boundary (O’Brien and Fleming, 1979) will be utilized. The software package East version 5.2.0 (East, 2008) 
will be used for the monitoring of the primary outcome. 
 
Because the Lan-DeMets approach is flexible, the number of “looks” does not have to be specified in advance 
and the time interval between “looks” does not have to be the same throughout the course of the trial.  
 
The formal monitoring for each co-primary outcome could occur independently or at the same time. It would 
be best if the first ‘look’ occurred when 1/3 of the patients had information available regarding death at 12 
months. 
 
 
Sensitivity Analysis 
 
This section addresses the impact of changes in assumptions and total sample size required for each trial 
(trial 1 and trial 2) of the EXAMPLE Trial. 
 
Lets assume for this exercise, that the assumed death rates for the EXPERIMENTAL group and the 
CONTROL group are reasonable. This implies that the non-inferiority margin is reasonable as well. 
 
This exercise will focus on the impact of: 
 
The ICC assumed 
The number of patients that do not consent to participate in the trial, and 
The number of patients that are Loss-to-Follow-up (LTF)  
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Impact of ICC: 
 
Single-Look Design 
Cluster size for each trial is 10 
ICC is the intra-cluster correlation coefficient. 
Deff = 1 + (n - 1)(ICC) 
  
No Cluster 
 
Large Cluster 
 
Medium Cluster 
 
Small Cluster 
ICC 
Deff 
0 
1 
0.001 
1.009 
0.01 
1.09 
0.05 
1.45 
0.1 
1.9 
0.3 
3.7 
Trial 1: effective sample size 
clusters 
13, 976 
NA 
14, 102 
1, 411 
15, 234
1, 524 
20, 266
2, 027 
26, 556 
2, 656 
51, 712 
5, 172 
Trial 2: effective sample size 
clusters 
9, 978 
NA 
10, 068 
1, 007 
10, 876
1, 088 
14, 470
1, 447 
18, 960 
1, 896 
36, 920 
3, 692 
 
As you can see, as the ICC gets stronger in a positive sense (because the cluster size gets smaller), the required 
effective sample size gets larger. In most cases, a cluster size of 10 would be considered a small cluster --> thus 
requiring an ICC of 0.3. To be safe one would use an ICC=0.3 (unless pilot study data and/or the literature 
suggests otherwise).  In this case, the effective sample size for trial 1 would be 51, 712 patients (5, 172 clusters) 
and the effective sample size for trial 2 would be 36, 920 patients (3, 692 clusters). 
≤
 
Impact of Loosing Patients: 
 
Now, we need to inflate the effective sample size of each trial to compensate for loosing patients due to non-
consent or LTF. Lets assume the following “lost patient” rates: 5%, 10%, 15%, and 20%. Lets also assume 
the “lost patient” rate is non-differential (i.e., the rate is the same for each treatment group, for each 
physician-month, etc). NOTE: This probably is not the case, we probably will have differential “lost patient” 
rates but to simplify this exercise, we will assume they are non-differential. Lets also just focus on the 
resulting effective sample sizes for trial 1 and trial 2 when a “small cluster” is considered, ICC= 0.3. We will 
define the total sample size as [effective sample size x (1+”lost patient” rate)]; where the “lost patient” rate is 
a proportion. 
 
 
 Single-Look Design 
 Small Cluster 
ICC=0.3 
Lost patient rate 
5% 
Lost patient rate 
10% 
Lost patient rate 
15% 
Lost patient rate 
20% 
 Effective sample 
size 
Number of 
clusters 
Total sample size 
Total number of 
clusters 
Total sample size 
Total number of 
clusters 
Total sample size 
Total number of 
clusters 
Total sample size 
Total number of 
clusters 
Trial 
1 
51, 712 
5, 172 
54, 298 
5, 430 
56, 884 
5, 689 
59, 470 
5, 947 
62, 056 
6, 206 
Trial 
2 
36, 920 
3, 692 
38, 766 
3, 877 
40, 612 
4, 062 
42, 458 
4, 246 
44, 304 
4, 431 
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As you can see, as the “lost patient” rate gets larger, the required total sample size gets larger. Thus, if we 
assume an ICC=0.3 and a “lost patient” rate of 20%, then the total sample size for trial 1 would be 62, 056 
patients (6, 206 clusters). The total sample size for trial 2 would be 44, 304 patients (4, 431 clusters).  
Therefore, 106, 360 patients would be required (10, 637 clusters) for the EXAMPLE Trial. 
 
Lets hope this is not the case! However, this exercise shows you the impact of the ICC that is assumed and the 
“lost patient” rate that is assumed on the total sample size requirements. 
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